Vericel CORP Form 4 insider transactions

Chief Medical Officer Jonathan Hopper exercised stock options and sold 10,000 shares of Vericel Corp stock at $49.83 per share on September 3, 2024.

Dominick Colangelo, President and CEO of Vericel Corp, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Kevin McLaughlin of Vericel Corp reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Vericel Corp's CEO, Dominick Colangelo, exercised stock options and sold shares of common stock on July 17 and 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sean Flynn, Chief Legal Officer of Vericel Corp, exercised stock options and sold 15,000 shares of common stock on July 16, 2024, according to a Form 4 filing with the SEC.

Joseph Mara Jr., CFO of Vericel Corp, sold 5,000 shares of common stock on July 12, 2024, at a price of $50 per share.

Jonathan Siegal, Principal Accounting Officer of Vericel Corp, sold 545 shares of common stock on July 5, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sean Flynn, Chief Legal Officer of Vericel Corp, reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.

Dominick Colangelo, President and CEO of Vericel Corp, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Lisa Wright reports the vesting of restricted stock units into 434 shares of Vericel Corp common stock on June 3, 2024.

Chief Medical Officer Jonathan Hopper exercised stock options and sold 10,000 shares of Vericel Corp stock on May 20, 2024, according to a Form 4 filing.

Michael Halpin, Chief Operating Officer of Vericel Corp, exercised stock options and acquired shares on May 17, 2024.

Vericel Corp's CEO, Dominick Colangelo, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Lisa Wright reports acquisition of common stock and derivative securities due to vesting of restricted stock units and stock options.

Director Robert Zerbe reports acquisition of Vericel Corp stock through vesting of restricted stock units and grant of stock options.

Director Paul Wotton reports transactions involving Vericel Corp stock, including the conversion and acquisition of restricted stock units and stock options.

Director Heidi Hagen reports acquisition of Vericel Corp common stock through vesting of Restricted Stock Units (RSUs) and grant of stock options.

Director Steven Gilman reports acquisition and disposal of Vericel Corp stock and derivative securities due to RSU vesting and option grants.

Director Kevin McLaughlin reports acquisition and disposal of Vericel Corp stock and derivative securities related to vesting of restricted stock units and stock options.

Director Alan Rubino reports acquisition of Vericel Corp common stock through vesting of Restricted Stock Units and grant of stock options.

Dominick Colangelo, President and CEO of Vericel Corp, exercised stock options and now holds a total of 220,752 shares of common stock.

Vericel Corp's CEO, Dominick Colangelo, exercised stock options and sold shares of common stock on April 17 and 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Alan L. Rubino exercised stock options to acquire 3,000 shares of Vericel Corp common stock at a price of $4.12 on April 9, 2024.

Director Robert L. Zerbe exercised stock options and sold shares of Vericel Corp under a pre-arranged Rule 10b5-1 trading plan.

Vericel Corp's CEO, Dominick Colangelo, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Sean Flynn, SVP and General Counsel of Vericel Corp, files an amended Form 4 to properly indicate a sale of 8,115 shares was executed under a pre-arranged 10b5-1 trading plan.

Michael Halpin, Chief Operating Officer of Vericel Corp, sold 7,874 shares of common stock at a price of $44.71 per share on March 11, 2024, under a pre-arranged 10b5-1 trading plan.

Principal Accounting Officer Jonathan Siegal of Vericel Corp reports the sale of 1,634 shares of common stock at $45 per share on March 7, 2024.

Sean C. Flynn, SVP, General Counsel of Vericel Corp, reports the sale of 8,115 shares of common stock at $45.33 per share on March 8, 2024.